



Participate in a clinical trial for adults with leptomeningeal metastases

What is this clinical trial about?

ReSPECT-LM is an FDA-approved Phase 1 clinical trial sponsored by Plus Therapeutics, Inc., a U.S. pharmaceutical company. The purpose of the trial is to determine the maximum dose, safety, and efficacy of a single administration of a new targeted radiation therapy, REYOBIQ[™] (rhenium re186 obisbameda), in adult patients diagnosed with leptomeningeal metastases from solid tumors.

What is leptomeningeal metastases?

Leptomeningeal metastases (also known as leptomeningeal carcinomatosis and leptomeningeal disease) occurs when cells from some types of cancer, such as breast cancer, lung cancer, and melanoma, spread to the meninges, cerebrospinal fluid (CSF), or both.

What qualifications are required?

To qualify for this trial, the patient must be:

- 18 years old or older, men and women
- Diagnosed with leptomeningeal metastases
- Able to undergo an MRI scan
- Available for screening, treatment, and follow-up visits for up to 12 months
- No prior whole brain or spinal cord radiation therapy

Is patient reimbursement available?

Yes, \$300 compensation for time and travel.

Which patients are eligible?

This trial is for adult patients that have leptomeningeal metastases despite conventional treatment. Healthy volunteers are not needed for this trial.

Interested In Learning More?

If you are interested in learning more about the ReSPECT-LM clinical trial, please visit our website at <https://ReSPECT-Trials.com/LM>, provide your doctor with ClinicalTrials.gov identifier NCT05034497, or contact a trial coordinator.

Clinical Trial Sites and Principal Investigators

- > UT Health San Antonio - Andrew Brenner, M.D., Ph.D.
- > UT Southwestern Medical Center (Texas) - Michael Youssef, M.D.
- > Northwestern Memorial Hospital (Illinois) - Priya Kumthekar, M.D.
- > Ohio State University Cancer Center - Pierre Giglio, M.D.
- > Northshore Hospital (New York) - Michael Schulder, M.D.
- > Lenox Hill Hospital (New York) - Randy D'Amico, M.D.

Contact

- For questions, please email:
ReSPECT@PlusTherapeutics.com



NATIONAL TRIAL REFERENCE NUMBER: NCT05034497

When speaking with your doctor, please have the national trial reference number available.

Scan QR code to learn more